More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$486148521
EPS
-1.16
P/E ratio
--
Price to sales
6.22
Dividend yield
--
Beta
1.970967
Previous close
$17.35
Today's open
$17.30
Day's range
$17.20 - $18.61
52 week range
$8.50 - $19.15
CEO
--
Employees
127
Headquarters
Carlsbad, CA
Exchange
Nasdaq Global Select
Shares outstanding
27404088
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Carlsmed to Participate in Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that management will participate in the following investor conferences:
GlobeNewsWire • Nov 16, 2026

Carlsmed: The Reimbursement Reset Is Not Yet In The Numbers
Carlsmed is transitioning from a surgeon-driven to a hospital-driven adoption story, catalyzed by new DRG reimbursement effective October 1, 2026. Q3 2026 saw 65% revenue growth, and a gross margin expansion to 77.3% and the first quarter of positive operating leverage, with conservative Q4 guidance despite favorable tailwinds. Hospital incentives now align with surgeon preferences, potentially accelerating adoption, while aprevo demonstrates a 74% reduction in revision rates versus stock devices.
Seeking Alpha • Nov 14, 2026

These Analysts Boost Their Forecasts On Carlsmed After Strong Q3 Results
Carlsmed, Inc. (NASDAQ:CARL) on Tuesday posted upbeat third-quarter results.
Benzinga • Nov 11, 2026

Carlsmed Q3 Earnings Call Highlights
Carlsmed NASDAQ: CARL raised its full-year revenue outlook after third-quarter sales climbed 65%, as more surgeons adopted its personalized spine surgery products and procedure volume increased.
MarketBeat • Nov 11, 2026

Carlsmed, Inc. (CARL) Q3 2026 Earnings Call Transcript
Carlsmed, Inc. (CARL) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 11, 2026

Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance
Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2026.
GlobeNewsWire • Nov 10, 2026

Carlsmed, Inc. (CARL) Reports Q3 Loss, Tops Revenue Estimates
Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.4 per share a year ago.
Zacks Investment Research • Nov 10, 2026

Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026
CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.
GlobeNewsWire • Oct 27, 2026

Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System
CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior System at the North American Spine Society's 41st Annual Meeting (NASS) in San Antonio, TX. The launch follows a limited market evaluation that commenced in February 2026, with the first in human procedure completed on February 10, 2026.
GlobeNewsWire • Oct 14, 2026

Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that on September 28, 2026, it granted stock options to purchase 180,137 shares of the Company's common stock and 89,286 time-based restricted stock units (“RSUs”) to Richard Heppenstall, the Company's newly-hired Chief Financial Officer, as a material inducement to his employment.
GlobeNewsWire • Oct 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Carlsmed Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.